Heri Layi rolled up his sleeve in Bunia on 27 October and became part of medical history. The shot he received was Ervebo, the only licensed Ebola vaccine in the world — but it was being tested against a strain of the virus it was never designed to fight.
Bunia, the capital of Ituri province in the eastern Democratic Republic of Congo, is the epicentre of the worst Ebola outbreak the country has ever recorded. The virus behind it is Bundibugyo, a rare species of Ebola first identified in neighbouring Uganda in 2007. The outbreak began in May. As of 1 November, it had produced more than 10,500 confirmed cases and 5,126 deaths — and it is still spreading across eight provinces.
Until now, every approved Ebola vaccine and treatment was built for a different species, Zaire ebolavirus. Whether they work against Bundibugyo was an open question with no data behind it. That is what is changing in Bunia: four clinical trials are now running at once, testing vaccines and treatments against the strain that is actually killing people.
The four trials
Tumaini — the multi-vaccine trial. Named after the Swahili word for “hope”, Tumaini launched on 23 October in Bunia. It is designed to test several vaccine candidates inside a single trial, using ring vaccination — immunising the contacts of people with confirmed cases, the people at highest risk. Ervebo was the first vaccine tested, to see whether it also protects against Bundibugyo. On 3 November, the World Health Organization announced that two more candidates would join: ChAdOx1 BDBV, developed by the University of Oxford with India’s Serum Institute, and mRNA-1469, developed by the American company Moderna. This will be the first time vaccines built specifically for the Bundibugyo virus are evaluated during an outbreak. They will enter the trial once national approvals are granted. The trial is led by Congo’s National Institute for Biomedical Research with the University of Antwerp, in collaboration with the WHO.
Bravo — the field vaccine study. Launched on 19 September by Doctors Without Borders (MSF) in collaboration with the Congolese Ministry of Health, Bravo is also testing Ervebo against the Bundibugyo strain. As of 27 October, some 2,030 Congolese had been recruited. Bunia Hospital is the first site; the study aims to reach 20,000 participants, expanding to Mongbwalu, north-west of Bunia, and Butembo in neighbouring North Kivu province. The first results are not expected before spring 2027 — researchers must wait until confirmed cases occur among participants before they can measure whether the vaccine worked.
Partner — the treatment trial. The third study aims to increase the survival chances of people already infected. Since early July it has been testing a combination of the antiviral remdesivir and a monoclonal antibody cocktail called MBP134. As of 27 October, MBP134 had been administered to 755 patients, including children. Early results are expected in the coming months.
Ebo-Pep — protection for the most exposed. The fourth study is testing two antivirals derived from the same molecule to protect high-risk contacts of Ebola patients: obeldesivir, and — for pregnant women and children — remdesivir.
Why Bundibugyo is different
Ebola is not one virus but a family. The Zaire species caused the catastrophic West African epidemic of 2014–2016 and most outbreaks since, which is why every licensed vaccine and treatment was aimed at it. Bundibugyo is rarer and less studied — and it has killed before. The current outbreak is the largest in the DRC’s history, larger even than the 2018–2020 epidemic in the country’s east that killed more than 2,200 people.
The numbers carry a warning of their own. The European Centre for Disease Prevention and Control has cautioned that the figures are still under review and the outbreak may be wider than detected. The centre in Bunia that treated patients closed in October after cases in the city dropped sharply from late September — a hopeful sign, but the epidemic has spread to eight provinces, and the trials’ results will not arrive until well into next year.
Why this matters
For fifty years, since the virus was first discovered in a Congolese laboratory in 1976, the DRC has been the place where Ebola is studied in the aftermath. This time, the science is happening during the outbreak, in the city where people are dying — and the people taking part, like Heri Layi, are Congolese volunteers, not subjects flown in from elsewhere.
That matters beyond Congo. Bundibugyo has crossed borders before, and a vaccine or treatment proven against it would fill a gap in the world’s defences that has been open since the strain was discovered. The trials in Bunia are slow, careful work, and their answers will not come until 2027. But for the first time in this outbreak, the question is not whether anything can be done — it is whether what is being done works.
Related: Kenya confirmed a second Ebola case last month — both were linked, though the outbreak later grew to 9 cases, with 2 deaths — and our Explains piece on the invisible pandemic of antimicrobial resistance.
Source: UN News — Two new Ebola vaccines to join DR Congo clinical trial
Correction: An earlier version of this article stated that neither of Kenya’s first two Ebola cases had spread further. It has been updated to reflect that the outbreak later grew to 9 cases, with 2 deaths. 15 November 2026.
